PRLR and breast carcinoma: Finally, targeting the YAP-CCN2 pathway with the pharmacological inhibitor Verteporfin (VPF) restored PRL/PRLR induced-differentiation features in breast cancer cells and re-established proper intercellular junctional adherence, promoted luminal differentiation and suppressed stem-cell marker expression.